GlassScriptPhysician profile
Ghassan Kazmouz
NPI 1083787980
$10,675.20
in general payments reported to CMS, 2019-2025
34 companies · $653 in 2025
The $653 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,338 · 2020: $1,007 · 2021: $1,615 · 2022: $2,024 · 2023: $2,196 · 2024: $842 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,665 · Education: $26.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,664.86 |
| Education | $26.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,532.47 | 2019-2023 | Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $1,195.84 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $790.37 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $768.17 | 2019-2025 | Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $727.48 | 2021-2025 | Verquvo, Winrevair |
| Janssen Pharmaceuticals, INC | $718.73 | 2019-2024 | Xarelto |
| Impulse Dynamics (USA) INC. | $647.53 | 2022-2025 | Optimizer, Optimizer |
| Abbott Laboratories | $624.01 | 2019-2025 | Mitraclip, Jot Dx |
| Pfizer INC. | $556.55 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $523.25 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.87 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $228.27 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Edwards Lifesciences Corporation | $151.67 | 2022 | |
| Elutia, INC. | $138.91 | 2019 | |
| Amarin Pharma, INC. | $113.56 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $95.00 | 2021 | |
| Medtronic Vascular, INC. | $88.40 | 2019 | |
| Amgen INC. | $80.62 | 2020-2023 | Repatha |
| Angiodynamics, INC. | $57.08 | 2023 | Alphavac |
| Scpharmaceuticals INC. | $45.52 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.44 | 2021-2024 | |
| Lilly USA, LLC | $34.30 | 2025 | Mounjaro |
| Acist Medical Systems, INC. | $31.41 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $30.71 | 2024 | Arcalyst |
| Abiomed | $24.49 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.03 | 2020 | |
| Bridgebio Pharma, INC. | $21.48 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $20.56 | 2024 | Inpefa |
| Medtronic, INC. | $20.55 | 2022 | |
| Chiesi USA, INC. | $19.91 | 2019 | |
| Medicomp INC | $17.75 | 2023 | Telepatch Cardiac Monitor |
| Tactile Systems Technology INC | $16.24 | 2022 | |
| Baxter Healthcare | $15.03 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Bardy Diagnostics, INC. | $14.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghassan Kazmouz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.